Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Beth Karlan

Showing results (21-30 of 82) with videos related to

Pageof 9
Sort By:
JAMA Surgery|November 6, 2014
Breast cancer following ovarian cancer in BRCA mutation carriersAlexandra Gangi, Ilana Cass, Daniel Paik, et al.
Plos One|January 11, 2011
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancerLei Zhang, Hua Xiao, Scott Karlan, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Gynecologic Oncology|September 28, 2011
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerSarah F Adams, Evelyn B Marsh, Wafic Elmasri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remissionStanley B Kaye, Louis Fehrenbacher, Robert Holloway, et al.
Fertility and Sterility|December 25, 2015
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationJacek Gronwald, Karen Glass, Barry Rosen, et al.
Gynecologic Oncology|September 16, 2023
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survivalLeah A Marsh, Teresa H Kim, Mingyan Zhang, et al.
Gynecologic Oncology|September 3, 2005
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Susan L Neuhausen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
Activation of the MEK-S6 pathway in high-grade ovarian cancersAviva P Ventura, Sabarinath Radhakrishnan, Ann Green, et al.
Gynecologic Oncology|May 11, 2026
Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventyEliya Shachar, Gilat Rotkop, Roni Haas, et al.
Pageof 9

Showing results (21-30 of 82) with videos related to

Sort By:
Pageof 9
JAMA Surgery|November 6, 2014
Breast cancer following ovarian cancer in BRCA mutation carriersAlexandra Gangi, Ilana Cass, Daniel Paik, et al.
Plos One|January 11, 2011
Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancerLei Zhang, Hua Xiao, Scott Karlan, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
Gynecologic Oncology|September 28, 2011
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerSarah F Adams, Evelyn B Marsh, Wafic Elmasri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remissionStanley B Kaye, Louis Fehrenbacher, Robert Holloway, et al.
Fertility and Sterility|December 25, 2015
Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutationJacek Gronwald, Karen Glass, Barry Rosen, et al.
Gynecologic Oncology|September 16, 2023
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survivalLeah A Marsh, Teresa H Kim, Mingyan Zhang, et al.
Gynecologic Oncology|September 3, 2005
Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriersJoanne Kotsopoulos, Jan Lubinski, Susan L Neuhausen, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
Activation of the MEK-S6 pathway in high-grade ovarian cancersAviva P Ventura, Sabarinath Radhakrishnan, Ann Green, et al.
Gynecologic Oncology|May 11, 2026
Real-world genetic testing data of ovarian cancer patients: Informing counseling and risk reduction in patients over age seventyEliya Shachar, Gilat Rotkop, Roni Haas, et al.
Pageof 9